miR-660: A novel regulator in human cancer pathogenesis and therapeutic implications

Area of Science:

• Molecular Biology
• Genetics
• Cancer Research

Background:

• MicroRNAs (miRNAs) are crucial regulators of gene expression.
• miR-660, located on chromosome Xp11.23, exhibits abnormal expression in various cancers.
• Its function is complicated by regulation from 8 competing endogenous RNAs (ceRNAs).

Purpose of the Study:

• To comprehensively elucidate the aberrant expression patterns, biological functions, and regulatory networks of miR-660 and its ceRNAs.
• To investigate the intricate signaling pathways implicated in miR-660's role in cancer.
• To explore the potential of miR-660 as a therapeutic target and biomarker.

Main Methods:

• Bioinformatic analysis to identify miR-660 targets and ceRNAs.
• Pathway analysis to map miR-660's involvement in key cancer signaling cascades (PI3K/AKT/mTOR, STAT3, Wnt/β-catenin, p53, NF‑κB, RAS).
• Literature review and data synthesis to consolidate current knowledge on miR-660's function in different cancer types and its role in chemoresistance.

Main Results:

• miR-660 targets 19 genes involved in 6 critical cancer-related pathways.
• It influences fundamental cellular processes including cell cycle, proliferation, apoptosis, and invasion/migration.
• miR-660 contributes to resistance against chemotherapies like cisplatin, gemcitabine, and sorafenib in lung, pancreatic, and liver cancers.

Conclusions:

• miR-660 is a significant regulator in cancer, impacting multiple oncogenic pathways and chemoresistance.
• Its complex ceRNA network adds layers to its functional regulation.
• Findings provide a framework for future research into miR-660 for cancer diagnosis and treatment, potentially enhanced by nanocarrier delivery systems like liposomes.